Japan Health Ministry To Review Study Exonerating Tamiflu
This article was originally published in PharmAsia News
Executive Summary
Japan's Health Ministry is expected to cancel a warning it had ordered on Roche's Tamiflu (oseltamivir) for teenagers after a study found no link to mental problems. The government-funded study completed by an Osaka City University professor found that children given the flu vaccine did not demonstrate psychotic behavior beyond normal levels. The ministry will use the study for a report of its own and a review of it by its drug safety committee, according to a ministry official. Tamiflu was required to carry the warning label after reports of psychotic behavior among youth under the age of 18 who had received the drug. (Click here for more
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.